Goldman Sachs has adopted a more cautious stance on European chemicals stocks after concluding two unwelcome developments have undermined the industry's near-term recovery. In a note led by Georgina Fraser, the bank said both sharper-than-anticipated demand erosion and stronger Chinese export competition have trimmed the sector's potential to rebound.
The firm implemented seven rating changes across its European chemicals coverage. Givaudan and Clariant were upgraded, while DSM-Firmenich, Syensqo, Symrise, Evonik and Arkema were downgraded. Givaudan shares moved up about 1% following the upgrade, and the group of downgraded names fell in a range between 1% and 6%. Separately, Clariant's stock traded about 2.7% lower on the same session.
Goldman's research team emphasised two central points in explaining the shift: "Two unexpected factors have materialised that make us more cautious: 1) demand destruction has been greater and swifter than we expected, and 2) stronger China export pressure and feedstock flexibility have eaten up much of the market share opportunity for EU chemicals," the analysts wrote.
The bank noted that the STOXX Europe 600 Chemicals index has advanced 11% since its December 2025 trough, outpacing the broader STOXX Europe 600. Nonetheless, Goldman warned that "renewed downside risks are materialising," and said it no longer expects the kind of cyclical improvement that had been previously contemplated. Instead, the team wrote that their forecasts are now "increasingly driven by pricing at the expense of volumes."
On the outlook, Goldman projects average organic sales growth of roughly 5% in 2026 and 3% in 2027 for European chemicals. It also expects margins to improve marginally, rising about 60 basis points between 2025 and 2027.
Given a landscape the analysts describe as one where a new inflation cycle may be emerging, the bank is shifting focus toward companies with defensive pricing power and secular growth exposure. Goldman highlighted Novonesis and Air Liquide as its top picks, saying these businesses are best positioned to deliver differentiated growth and stronger margin progression.
Goldman's individual company adjustments reflected a mix of company-specific and market-wide considerations. Givaudan received a two-notch upgrade to Buy from Sell, with the bank citing the company's "superior pricing power". The analysts pointed to Givaudan's commercial profile, noting that approximately 96% of its sales come from customer-specific formulations, plus the benefits of scale among multinational customers and comparatively robust R&D investment.
Clariant was upgraded to Neutral from Sell. The bank cited Clariant's demonstrated ability to pass through input cost inflation within its Care Chemicals division as a basis for the more positive view.
Several downgrades reflected concerns about exposure to discretionary markets or reliance on single-ingredient sales. DSM-Firmenich was cut to Sell from Neutral; Goldman said the company's mid-term guidance, which assumes a 1-2 percentage point uplift from normalisation, looks "increasingly optimistic," and highlighted DSM-Firmenich's greater exposure to discretionary end markets and single-ingredient sales as limitations on pricing power.
Syensqo was downgraded to Sell from Buy. Goldman noted the stock's 55% rally since its March trough and said that rally "embeds a high degree of execution" in margin recovery that faces meaningful downside risk from weakening volumes in automotive, construction and consumer electronics.
Symrise and Evonik were both moved to Neutral from Buy. Arkema was also lowered to Neutral. Goldman said geopolitical developments in the Middle East have undermined its earlier thesis, which had leaned on U.S. manufacturing and construction exposure as tailwinds.
The bank's revisions reflect a recalibration of risk-return trade-offs across the sector, with valuation and near-term demand dynamics prompting a tilt toward companies with predictable pricing mechanics and secular end-market exposure.
Market impact and positioning
Goldman's note signals a shift away from a broad cyclical recovery thesis for European chemicals. Instead, the bank is prioritising names where pricing resilience and structural growth prospects can offset volatile volumes and increased competition from Chinese exporters. The revision of ratings is intended to reflect those differentiated prospects across the coverage universe.